CN110290793A - 天然组合激素替代制剂和治疗 - Google Patents

天然组合激素替代制剂和治疗 Download PDF

Info

Publication number
CN110290793A
CN110290793A CN201780086119.7A CN201780086119A CN110290793A CN 110290793 A CN110290793 A CN 110290793A CN 201780086119 A CN201780086119 A CN 201780086119A CN 110290793 A CN110290793 A CN 110290793A
Authority
CN
China
Prior art keywords
estradiol
progesterone
subject
auc
estrone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780086119.7A
Other languages
English (en)
Chinese (zh)
Inventor
朱莉娅·M·阿玛迪奥
布莱恩·A·伯尼克
塞巴斯蒂安·米尔金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TherapeuticsMD Inc
Original Assignee
TherapeuticsMD Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TherapeuticsMD Inc filed Critical TherapeuticsMD Inc
Publication of CN110290793A publication Critical patent/CN110290793A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201780086119.7A 2016-12-05 2017-12-05 天然组合激素替代制剂和治疗 Pending CN110290793A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662430339P 2016-12-05 2016-12-05
US62/430,339 2016-12-05
US201762481060P 2017-04-03 2017-04-03
US62/481,060 2017-04-03
PCT/US2017/064788 WO2018136161A1 (en) 2016-12-05 2017-12-05 Natural combination hormone replacement formulations and therapies

Publications (1)

Publication Number Publication Date
CN110290793A true CN110290793A (zh) 2019-09-27

Family

ID=62908279

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780086119.7A Pending CN110290793A (zh) 2016-12-05 2017-12-05 天然组合激素替代制剂和治疗

Country Status (11)

Country Link
EP (1) EP3548036A4 (cg-RX-API-DMAC10.html)
JP (1) JP2020504093A (cg-RX-API-DMAC10.html)
KR (1) KR20200018383A (cg-RX-API-DMAC10.html)
CN (1) CN110290793A (cg-RX-API-DMAC10.html)
AU (1) AU2017394679A1 (cg-RX-API-DMAC10.html)
BR (1) BR112019011655A2 (cg-RX-API-DMAC10.html)
CA (1) CA3045024A1 (cg-RX-API-DMAC10.html)
IL (1) IL267023A (cg-RX-API-DMAC10.html)
MX (1) MX2019006513A (cg-RX-API-DMAC10.html)
RU (1) RU2019115913A (cg-RX-API-DMAC10.html)
WO (1) WO2018136161A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220105107A1 (en) * 2020-10-01 2022-04-07 Michael Liguori Bioidentical progesterone cream infused with nanoemulsified cbd
GB202316026D0 (en) * 2023-10-19 2023-12-06 Theramex Hq Uk Ltd Methods of prevention or treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1684690A (zh) * 2002-09-30 2005-10-19 舍林股份公司 用于激素替代疗法的17β－雌二醇/左炔诺孕酮经皮贴剂
US20130338123A1 (en) * 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150342963A1 (en) * 2014-05-22 2015-12-03 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208225A (en) * 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US6901278B1 (en) * 2002-01-29 2005-05-31 Morris Notelovitz Methods for reducing the risk of breast cancer in and improving the health of women

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1684690A (zh) * 2002-09-30 2005-10-19 舍林股份公司 用于激素替代疗法的17β－雌二醇/左炔诺孕酮经皮贴剂
US20130338123A1 (en) * 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150342963A1 (en) * 2014-05-22 2015-12-03 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies

Also Published As

Publication number Publication date
IL267023A (en) 2019-07-31
RU2019115913A (ru) 2021-01-15
AU2017394679A1 (en) 2019-06-13
WO2018136161A1 (en) 2018-07-26
WO2018136161A9 (en) 2019-08-22
EP3548036A4 (en) 2020-06-17
RU2019115913A3 (cg-RX-API-DMAC10.html) 2021-03-19
KR20200018383A (ko) 2020-02-19
MX2019006513A (es) 2019-08-14
JP2020504093A (ja) 2020-02-06
BR112019011655A2 (pt) 2019-10-22
EP3548036A1 (en) 2019-10-09
CA3045024A1 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
US20180221389A1 (en) Natural combination hormone replacement formulations and therapies
Archer et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial
Duijkers et al. Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: results of a phase II dose-finding pilot study
US20190247401A1 (en) Natural combination hormone replacement formulations and therapies
US10398708B2 (en) Vaginal inserted estradiol pharmaceutical compositions and methods
Skouby et al. A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 μg ethinyl estradiol combined with 100 μg levonorgestrel
KR20080108120A (ko) 국소 에스트로겐 부족으로 야기된 병태의 예방 및 치료 방법
US11266661B2 (en) Vaginal inserted estradiol pharmaceutical compositions and methods
KR20170005819A (ko) 천연 복합 호르몬 대체 제형 및 요법
US20190343771A1 (en) Vaginal inserted estradiol pharmaceutical compositions and methods
Kaunitz et al. Low-dose levonorgestrel and ethinyl estradiol patch and pill: a randomized controlled trial
BR112019025914A2 (pt) composições farmacêuticas de estradiol para inserção vaginal e métodos
JP7827774B2 (ja) 月経困難症治療用組成物
Apgar Dysmenorrhea and dysfunctional uterine bleeding
EP3548036A1 (en) Natural combination hormone replacement formulations and therapies
Akintomide et al. Nomegestrol acetate/17-beta estradiol: a review of efficacy, safety, and patient acceptability
US20230302015A1 (en) Natural combination hormone replacement formulations and therapies
KR20180100567A (ko) 질 삽입식 에스트라디올 약제학적 조성물 및 방법
Davis et al. Drugs for the treatment of menopausal symptoms
US20250387339A1 (en) Vaginal inserted estradiol pharmaceutical compositions and methods
Gaspard et al. ORIGINAL STUDY
WO2020081726A1 (en) Methods of treating menopausal symptoms using low dose progesterone
Rybacki HOW SUPPLIED
BR112016009008B1 (pt) Uso de estradiol e/ou hemi-hidrato de estradiol e de um agente solubilizante compreendendo um óleo de cadeia média para a preparação de um pessário para o tratamento de atrofia vulvovaginal e pessário que compreende estradiol

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190927